

Elsevier Editorial System(tm) for
Reproductive BioMedicine Online
Manuscript Draft

Manuscript Number:

Title: Variation in antral follicle counts (AFC) at different times in the menstrual cycle - does it matter?

Article Type: Full Length Article

Section/Category: Eggs and ovary

Keywords: : ovarian reserve testing, AFC, AMH, ultrasound

Corresponding Author: Mr. Dimitrios Mavrelos, MBBS MD

Corresponding Author's Institution: University College London

First Author: Dimitrios Mavrelos, MBBS MD

Order of Authors: Dimitrios Mavrelos, MBBS MD; Ali Al Chami; Vikram Talaulikar; Elizabeth Burt; Lisa Webber; Ephraim Yasmin

Abstract: Our study examined AFC variation across the cycle and its impact on clinical management. We documented AFC in early (iAFC) and late follicular phase (sAFC) in 79 women. We examined absolute agreement between iAFC and sAFC as well as agreement for categorisation into categories of risk of extremes of ovarian response. We compared controlled ovarian stimulation (COS) protocols designed with iAFC and sAFC and the predictive value of iAFC and sAFC for extremes of ovarian response in women who underwent COS. We found significant difference between iAFC and sAFC (16 [IQR 9 - 23] vs. 13 [IQR 7 - 21], $p=0.001$) with moderate agreement for the classification into at risk of extremes of response ($k=0.525$). There was good agreement for protocol selection based on either AFC ($k=0.750$) and starting gonadotrophin dose (CCC 0.970 [95% CI 0.951 - 0.982]). iAFC and sAFC maintained good predictive value for poor ovarian response and risk of ovarian hyperstimulation syndrome (AUC 0.932 [0.832 - 1.0], 0.927 [0.850 - 1.0]) and (AUC 0.701 [0.533 - 0.869], 0.737 [0.504 - 0.971]) respectively. AFC varies across the menstrual cycle but this does not have a significant impact on COS protocol design and prediction of extremes of ovarian response.

Suggested Reviewers:

Opposed Reviewers:

Dr Dimitrios Mavrelos
Reproductive Medicine Unit
University College London Hospital
25 Grafton Way
NW1 2BU
London, UK

Professor Garcia – Velasco
Editor in Chief
Reproductive BioMedicine Online

Dear Professor Garcia-Velasco,

Please find attached our manuscript on the variation between antral follicle counts determined in the early and late follicular phases of the menstrual cycle. We aimed to describe the variation and explore whether this variation significantly impacts clinical decisions.

We look forward to hearing from you in due course.

Kind regards

Dr Dimitrios Mavrelos

Variation in antral follicle counts (AFC) at different times in the menstrual cycle –
does it matter?

Short title: Variation in AFC during the menstrual cycle

Dimitrios Mavrelos Ali Al Chami, Vikram Talaulikar, Elizabeth Burt, Lisa Webber,
Ephia Yasmin

Reproductive Medicine Unit, University College London Hospital, 25 Grafton
Way, London NW1 2BU, United Kingdom

Corresponding author

Dimitrios Mavrelos

Reproductive Medicine Unit

University College London Hospital

25 Grafton Way

NW1 2BU

United Kingdom

d.mavrelos@ucl.ac.uk

Abstract

1
2 Our study examined AFC variation across the cycle and its impact on clinical
3 management. We documented AFC in early (iAFC) and late follicular phase
4 (sAFC) in 79 women. We examined absolute agreement between iAFC and sAFC
5 as well as agreement for categorisation into categories of risk of extremes of
6 ovarian response. We compared controlled ovarian stimulation (COS) protocols
7 designed with iAFC and sAFC and the predictive value of iAFC and sAFC for
8 extremes of ovarian response in women who underwent COS. We found
9 significant difference between iAFC and sAFC (16 [IQR 9 – 23] vs. 13 [IQR 7 – 21],
10 p=0.001) with moderate agreement for the classification into at risk of extremes
11 of response (k=0.525). There was good agreement for protocol selection based
12 on either AFC (k=0.750) and starting gonadotrophin dose (CCC 0.970 [95% CI
13 0.951 – 0.982]). iAFC and sAFC maintained good predictive value for poor
14 ovarian response and risk of ovarian hyperstimulation syndrome (AUC 0.932
15 [0.832 – 1.0], 0.927 [0.850 – 1.0]) and (AUC 0.701 [0.533 – 0.869], 0.737 [0.504 –
16 0.971]) respectively. AFC varies across the menstrual cycle but this does not
17 have a significant impact on COS protocol design and prediction of extremes of
18 ovarian response.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 Keywords: ovarian reserve testing, AFC, AMH, ultrasound
58
59
60
61
62
63
64
65

Introduction

1
2 Assessment of the biomarkers of ovarian response is integral to the work up of
3 women presenting with subfertility. Biomarkers used in routine clinical include
4 anti - mullerian hormone (AMH), early follicular phase follicle stimulating
5 hormone (FSH) and early follicular phase antral follicle count (AFC). AMH is the
6 marker of ovarian reserve with least intracycle variability (Deb et al. 2013)
7 making it the most convenient as it can be performed at any point in the cycle
8 (Iliodromiti et al. 2014). FSH is a late marker of poor ovarian response
9 (Broekmans et al. 2006; Iliodromiti et al. 2014) and alone is not considered
10 adequate to design a protocol of controlled ovarian stimulation (COS) (Broer et
11 al. 2013). AFC by transvaginal ultrasound in the early follicular phase of the
12 cycle continues to be part of initial investigations for women presenting with
13 subfertility as the test can be easily performed directly by the treating clinician
14 with immediately available results (Scheffer et al. 2002).

15
16
17
18
19
20
21
22
23
24
25
26
27
28 An inherent concern with use of AFC as a biomarker is its operator dependence
29 (Iliodromiti and Nelson 2015). Another concern has been timing of AFC
30 determination with regard to menstrual cycle. Current recommendations limit
31 AFC determination to the early follicular phase in an attempt at standardization
32 (Broekmans et al. 2010). However this restriction creates anxiety for patients as
33 it creates a narrow time window within which to complete their assessments
34 and results in considerable administrative burden for clinics to schedule
35 appointments. It also increases the number of visits for the patient to the clinic.

36
37
38
39
40
41
42
43
44 The aim ovarian response biomarker determination is to identify patients at risk
45 extremes of ovarian response and individualize COS protocols to obtain an
46 optimal result (Bosch and Ezcurra 2011). A degree of intracycle variability that
47 does not jeopardize these objective may acceptable in clinical practice. Indeed
48 some data on this subject exist, a retrospective study of over 3,000 patients
49 argued that the clinical usefulness of AFC remains unchanged across the cycle
50 (Rombauts et al. 2011).

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The aim of our study was to examine whether AFC determination in the late follicular phase of the cycle would impact selection of COS protocol and the accuracy of AFC to predict extremes of ovarian response.

Materials and Methods

The study took place in the Reproductive Medicine Unit (RMU) of University College London Hospital (UCLH) between April 2014 and June 2015. We sought the opinion of the Joint Research Office of the hospital and were advised that formal ethics approval was not required as the project involved no change in routine clinical practice.

We included women with a regular 28 – 34 day cycle referred for fertility investigation. All women referred to the clinic undergo a transvaginal ultrasound scan between days 2 to 5 of their menstrual cycle for examination of the pelvis, uterus and assessment of the AFC (Voluson E8 Expert, GE Medical Systems, Zipf, Austria). All women undergo a second ultrasound examination on day 8 – 12 of their cycle for Hysterosalpingo – Contrast - Sonography (HyCoSy) or 3D saline infusion sonohysterography (3D SIS). At the second examination the ovaries are routinely examined and a repeat AFC is performed. Determination of the antral follicle count is performed according to internationally agreed guidance (Broekmans et al. 2010). Briefly, we identify each ovary and examine it in two planes to determine its limits. We then sweep the complete ovary in the transverse plane to identify and count all follicles 2 – 10mm in diameter. Abdominal pressure is applied in cases of difficult visualization. All examinations were performed by three operators (DM, AA, and VT).

Further routine investigations in our unit for women with subfertility are serum AMH (Beckman Coulter AMH Gen II ELISA) and day 2 -5 FSH determinations. AMH and FSH results were archived on a database which is not accessed during ultrasound examinations thereby blinding operators to these results.

We created a spreadsheet (Excel 11 for Mac, Microsoft Corp.) to record the women's demographic details, day of the cycle the first examination took place

1 and the early follicular phase AFC (iAFC) in each ovary. We created a second
2 spreadsheet to document the day of the cycle the second examination took place
3 and the late follicular phase AFC (sAFC) in each ovary as well as the presence
4 and mean diameter of a dominant follicle in either ovary. Once all examinations
5 were complete the databases were amalgamated and the AMH and FSH results
6 were added.
7
8
9

10
11
12 We used the National Institute of Clinical Excellence (NICE) fertility guideline to
13 define categories of “at risk of low response”, “normal response” and “at risk of
14 high response” after COS (NICE 2013) i.e.: i) total AFC ≤ 4 and ≥ 16 ii) AMH
15 ≤ 5.4 pmol/l and ≥ 25.0 respectively. We classified women into the various
16 categories based on each of AMH, iAFC and sAFC.
17
18
19
20
21
22
23

24 During the study we excluded women with amenorrhea or irregular cycles as we
25 would not be able to time AFC determination, women with known pathologies
26 such as endometriosis or large fibroids that displace the ovaries and affect the
27 accuracy of AF counts. We also excluded women over 40 years old, those with a
28 BMI > 30 and those who did not tolerate HyCoSy or 3D SIS examination.
29
30
31
32
33
34

35 In order to examine the interobserver variability in AFC determination in our
36 unit, a set of ovarian 3D volumes were obtained by DM and AA from a different
37 cohort of patients and stored. The volumes were anonymised and each operator
38 was asked examine the volumes and record the total AFC for each woman in
39 individualized Excel spreadsheets. Each operator was blind to other operators'
40 findings.
41
42
43
44
45
46
47

48 COS protocols in our unit are individualized according to age, body mass index
49 (BMI), AMH, AFC, FSH and clinician preference (Bosch and Ezcurra 2011). To
50 further explore the potential impact of performing AFC in the late follicular
51 phase criteria we created two Excel spreadsheets with clinical and ORT data for
52 each case. Both spreadsheets contained age, AMH, FSH and a total AFC value. One
53 spreadsheet contained the iAFC and the other sAFC. The cases were arranged in
54 random order and there were no identifiers. EY was blinded as to whether the
55
56
57
58
59
60
61
62
63
64
65

1 spreadsheet contained iAFC or sAFC and was asked to select a COS protocol. The
2 protocols we routinely use include : (i) long agonist, (ii) long agonist with
3 withdrawal of GnRHa on day 3 of stimulation, (iii) antagonist and (iv) no COS. EY
4 also selected starting dose of gonadotrophin dose (human menopausal
5 gonadotrphin, hMG) for each case.
6
7
8
9

10 For women who underwent a COS cycle we collected data on IVF protocol, total
11 gonadotrophin dose, serum oestradiol concentration at trigger and the total
12 number of oocytes retrieved. We classified women who had ≤ 4 oocytes retrieved
13 as “poor response” and ≥ 16 oocytes retrieved as “at risk of ovarian
14 hyperstimulation syndrome (OHSS)”.
15
16
17
18
19
20
21

22 Statistical analysis

23 Interobserver variability was assessed by calculating Lin’s concordance
24 correlation coefficient (CCC), plotting Bland – Altman plots and calculating the
25 absolute and relative limits of agreement (LoA) between observers. To assess
26 agreement between iAFC and sAFC we calculated Lin’s CCC, plotted Bland –
27 Altman charts and calculated LoA. To examine the impact of AFC timing on i)
28 classification into categories of predicted response to COS and ii) on COS
29 protocol selection we constructed 2xn tables to calculate Cohen’s κ for category
30 agreement between iAFC and sAFC. To further assess the impact of AFC timing
31 on COS protocol selection we calculated the CCC for gonadotrophin starting dose
32 in COS protocols designed based on iAFC and sAFC. To assess the diagnostic
33 value of iAFC, sAFC and AMH for the identification of poor responders to COS and
34 those at risk of OHSS we constructed receiver operating curves (ROC) and
35 calculated the area under the curve (AUC). We used SPSS for statistical analysis.
36 (SPSS statistics, ver. 22, IBM. Corp.)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Results

53 Inter-observer variability

54 During the study period bilateral 3D ultrasound ovarian volumes were collected
55 from 24 women. There was good or very good interobserver agreement for off -
56
57
58
59
60
61
62
63
64
65

1 line AFC determination. The CCC for total AFC determination between DM and
2 AA was 0.967 (95% CI 0.926 – 0.985) and 0.992 (95% CI 0.983 – 0.996) between
3 DM and VT. The LoA for DM and AA was between -6.7 and 8.6 or -14%/6% of
4 the mean AFC. The LoA for DM and VT was between -1.5 and 4.0 or -5%/14% of
5 the mean AFC (Figure 1 and 2).
6
7
8
9

10 iAFC and sAFC agreement

11 During the study period 103 women under underwent both early and late
12 follicular phase total AFC determination by one of the observers. 24 women were
13 excluded because the interval between examinations was >6 months. The
14 median age of women participating in the study was 35 years (IQR 32 – 38). The
15 median day of the cycle for iAFC determination was day 4 (range 2 – 5). The
16 median day of the cycle for sAFC determination was day 9 (8 – 11). The median
17 number of cycles between iAFC and sAFC was 1 (IQR 0 – 3)
18
19
20
21
22
23
24
25
26

27 There was a significant difference between median iAFC and median sAFC (16
28 AFC [IQR 9 – 24] vs. 13 AFC [IQR 7 – 21], $p=0.001$). There was moderate
29 agreement between iAFC and sAFC for categorization into predicted low
30 response, normal response and risk of high response ($\kappa = 0.525$). 54/79
31 (68.4%, 95% CI 58.2 – 78.7) patients were allocated into the same categories by
32 iAFC and sAFC (Table 1).
33
34
35
36
37
38
39
40

41 The iAFC and sAFC showed moderate CCC (0.678, 95% CI 0.543 – 0.779) with
42 32.2% variation in AFC within the same subject between different cycle phases.
43 A Bland Altman plot showed a mean difference between measurements of 2
44 (95% CI 0.63 – 4.0) with LoA between -13 and 17. There was significant
45 inequality of variance between women with <13 follicles and the rest ($p=0.002$)
46 (Figure 3). The LoA in women with fewer follicles was -6 to 6 compared to -14 to
47 21 in those with more follicles.
48
49
50
51
52
53
54
55

56 In the blinded protocol design exercise there was good agreement between COS
57 protocol types selected based on iAFC and those based on sAFC ($\kappa = 0.750$).
58 There was good agreement for starting gonadotrophin dose between COS
59
60
61
62
63
64
65

1 protocols designed based on iAFC and sAFC with a CCC of 0.970 (95% CI 0.951 –
2 0.982).
3
4

5 41/80 women underwent a stimulated IVF cycle. The median total hMG was
6 2700 iu/L (IQR 1462.5 – 4275) and the median number of oocytes retrieved was
7 12 (IQR 6 – 15). There was a significant positive correlation between iAFC,
8 sAFC, AMH and the number of oocytes retrieved. 4/41 women (9.8%, 95% CI 0.7
9 – 18.9) had ≤ 4 oocytes retrieved and 7/41 (17.1%, 95% CI 5.6 – 28.6) had ≥ 16
10 oocytes retrieved. The AUC for prediction of poor response and risk of OHSS for
11 age, FSH, AMH, iAFC and sAFC is shown in Table 2.
12
13
14
15
16
17
18
19

20 Discussion

21 Our study aimed to examine whether performing AFC determination in the late
22 follicular phase would have an impact on the clinical management of infertile
23 women. Our results showed that there is a statistically significant difference
24 between AFCs determined in the early follicular and those determined in the late
25 follicular phase which leads to poor agreement between them. However this
26 poor agreement does not appear to have a significant impact on COS protocol
27 design and the predictive value of late follicular phase AFC for extremes of
28 ovarian response.
29
30
31
32
33
34
35
36
37
38

39 Our study is the first to prospectively examine AFC variation in a population of
40 infertile women which lends validity to our findings. Previous studies have
41 examined the intra cycle variation of AFC in healthy volunteers. Deb et al.
42 performed a study on 38 women scanned at 4 different instances in the same
43 cycle. They employed sonoAFC in a relatively young population (mean age 28
44 years) and found minimal AFC intra cycle variation, in the order of 6% (Deb et al.
45 2013). In contrast, van Disseldorp et al. in an older population of patients
46 (median age 33 years) report an approximately 30% intra cycle AFC variation
47 (van Disseldorp et al. 2010). This level of intra cycle variation led van Disseldorp
48 et al. to conclude that restricting AFC to the early follicular phase would improve
49 reliability of the test. Our results are similar to those by van Disseldorp et al. and
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 we confirmed that AFCs show significant variation reaching 30% between early
2 and late follicular phases of the cycle.
3
4

5 In contrast to van Disseldopr et al. in our study the majority of paired AFC
6 measurements were not performed in the same cycle but consecutive cycles but
7 never more than 6 cycles apart. While this interval restriction ensures that the
8 observed effect reflects inter and intra cycle variation rather than underlying age
9 related decline, it is not possible to discern directly from our results whether the
10 variation we observed is due to intra or inter cycle change. This would require
11 examinations in the same cycle followed by examinations in a subsequent cycle
12 which may be difficult to achieve. Others have examined the inter cycle variation
13 of early follicular AFCs and both Elter et al. and Bancsi et al. showed that AFC
14 exhibits significant inter cycle variability with the coverage interval of the
15 difference ranging to a minimum of +/- 6 follicles (Bancsi et al. 2004; Elter et al.
16 2005) . Compared to these authors we observed greater limits of agreement
17 between paired AFCs which may be due to our population's considerably higher
18 median AFC. When we restricted the population to women with less than total
19 13 follicles the limits of agreement in our study were identical to those previous
20 reports (+/- 6). This is despite the fact the determinations happened in different
21 cycle times. From this it would appear that two AFCs determined in different
22 cycles and different times in the cycle are not more variable than AFCs
23 determined in different cycles at the same cycle time.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 One of the purposes of biomarkers of ovarian response is to alert clinicians to the
44 risk of poor ovarian response to stimulation and, at the other end of the
45 spectrum, the risk of high response leading to OHSS. In this study we wanted to
46 examine whether the degree of AFC variation we and others have observed
47 would impact this categorisation. Indeed, we found only moderate agreement
48 between iAFC and sAFC for classification into ovarian reserve categories. The
49 majority of discrepancy appears in the classification into "at risk of high
50 response" category where 11 patients considered "at risk of high response" with
51 early follicular AFC would have been classified as "normal" by sAFC. It is
52 questionable however whether restriction to the early follicular phase would
53
54
55
56
57
58
59
60
61
62
63
64
65

1 have addressed this issue as it may represent intercycle variability rather than
2 intracycle variability and thus an inherent limitation of AFC. ORT is also used to
3 design treatment protocols for ovarian stimulation during an IVF cycle. (Broer et
4 al. 2013; Jayaprakasan et al. 2012). We showed here that using AFC determined
5 in the late follicular phase for the purpose of designing a COS protocol would not
6 have lead to a change in either type of protocol selected or starting
7 gonadotrophin dose. Finally it appears that AFC timing does not impact the
8 predictive ability of the test for extremes of response at the time of COS with
9 both iAFC and sAFC showing a similar area under the curve for the prediction of
10 poor response and risk of OHSS. This is consistent with the retrospective study
11 by Rombauts et al. showing that the AFC retains its predictive ability irrespective
12 of the time in the cycle it was determined (Rombauts et al. 2011).

23 AFC as a test of ovarian reserve has been criticized for substantial operator
24 dependency (Iliodromiti et al. 2014) . Nevertheless authors have shown that
25 there is adequate interobserver agreement for AFC determination using both 3D
26 and 2D transvaginal ultrasound (Scheffer et al. 1999). We aimed to produce a
27 pragmatic study and so did not restrict the operators included. In order to
28 assess the robustness of our results, we examined the reliability of AFC
29 determination in our unit. In agreement with Sheffer et al. we demonstrated
30 excellent ICC between operators included in this study suggesting that the AFC
31 variation we observed represents a real difference rather than inter observer
32 variability.

43 One of the reasons the current consensus restricts AFC timing to days 2 - 5 of the
44 cycle is an attempt to standardize AFC measurements (Broekmans et al. 2010).
45 However women dislike being scanned while menstruating and achieving this
46 timing creates unnecessary administrative burden for the clinic. Transvaginal
47 scanning provides a wealth of information beyond AFC and will remain an
48 integral part of infertility assessment. However the greater cycle stability and
49 operator independence of AMH suggest that AFC will become a complementary
50 test rather than a main ORT determinant. We show here that AFCs determined in
51 different cycle phases have significant statistical difference but similar clinical
52
53
54
55
56
57
58
59
60
61
62
63
64
65

validity. Based on our results it may be possible to combine AFC determination in the late follicular phase with other ultrasound based tests such as 3D SIS and HyCoSy without significant loss of clinically useful information.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2
3
4 Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Impact of
5 repeated antral follicle counts on the prediction of poor ovarian response
6 in women undergoing in vitro fertilization. *Fertil Steril* 2004; 81: 35-41.
- 7 Bosch EE, Zurra D. Individualised controlled ovarian stimulation (iCOS):
8 maximising success rates for assisted reproductive technology patients.
9 *Reprod Biol Endocrinol* 2011; 9: 82.
- 10 Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of
11 tests predicting ovarian reserve and IVF outcome. *Hum Reprod Update*
12 2006; 12: 685-718.
- 13 Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The
14 antral follicle count: practical recommendations for better
15 standardization. *Fertil Steril* 2010; 94: 1044-51.
- 16 Broer SL, et al. Added value of ovarian reserve testing on patient characteristics
17 in the prediction of ovarian response and ongoing pregnancy: an
18 individual patient data approach. *Hum Reprod Update* 2013; 19: 26-36.
- 19 Deb S, Campbell BK, Clewes JS, Pincott-Allen C, Raine-Fenning NJ. Intracycle
20 variation in number of antral follicles stratified by size and in endocrine
21 markers of ovarian reserve in women with normal ovulatory menstrual
22 cycles. *Ultrasound Obstet Gynecol* 2013; 41: 216-22.
- 23 Elter K, Sismanoglu A, Durmusoglu F. Intercycle variabilities of basal antral
24 follicle count and ovarian volume in subfertile women and their
25 relationship to reproductive aging: a prospective study. *Gynecol*
26 *Endocrinol* 2005; 20: 137-43.
- 27 Iliodromiti S, Nelson SM. Ovarian response biomarkers: physiology and
28 performance. *Curr Opin Obstet Gynecol* 2015; 27: 182-6.
- 29 Iliodromiti S, Anderson RA, Nelson SM. Technical and performance
30 characteristics of anti-Mullerian hormone and antral follicle count as
31 biomarkers of ovarian response. *Hum Reprod Update* 2014.
- 32 Jayaprakasan K, Chan Y, Islam R, Haoula Z, Hopkisson J, Coomarasamy A, Raine-
33 Fenning N. Prediction of in vitro fertilization outcome at different antral
34 follicle count thresholds in a prospective cohort of 1,012 women. *Fertil*
35 *Steril* 2012; 98: 657-63.
- 36 NICE (2013), 'Assessment and treatment of people with fertility problems',
37 (London), 19 - 20
- 38 Rombauts L, Onwude JL, Chew HW, Vollenhoven BJ. The predictive value of antral
39 follicle count remains unchanged across the menstrual cycle. *Fertil Steril*
40 2011; 96: 1514-8.
- 41 Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te Velde ER.
42 Antral follicle counts by transvaginal ultrasonography are related to age
43 in women with proven natural fertility. *Fertil Steril* 1999; 72: 845-51.
- 44 Scheffer GJ, Broekmans FJ, Bancsi LF, Habbema JD, Looman CW, Te Velde ER.
45 Quantitative transvaginal two- and three-dimensional sonography of the
46 ovaries: reproducibility of antral follicle counts. *Ultrasound Obstet Gynecol*
47 2002; 20: 270-5.
- 48 van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser
49 BC, Broekmans FJ. Comparison of inter- and intra-cycle variability of anti-
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Mullerian hormone and antral follicle counts. *Human reproduction*
(Oxford, England) 2010; 25: 221-27.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

		sAFC			
		Low response	Normal response	High response	Total
iAFC	Low response n (%)	2 (66.6)	1 (33.3)	0	3
	Normal response n (%)	5 (13.9)	27 (75.0)	4 (11.1)	36
	High response n (%)	0	11 (27.5)	29 (72.5)	40


Table 1: Agreement between iAFC and sAFC for categorization into at risk of low response (total AFC ≤ 4), normal and at risk of high response (total AFC ≥ 16) ($k = 0.525$)

	Area under the curve (95% CI)			
	Poor response		Risk of OHSS	
iAFC	0.932	(0.857 – 1.0)	0.701	(0.533 – 0.869)
sAFC	0.927	(0.850 – 1.0)	0.737	(0.504 – 0.971)
AMH	0.880	(0.762 – 0.998)	0.691	(0.485 – 0.898)
FSH	0.625	(0.334 – 0.917)	-	-
Age	0.720	(0.509 – 0.931)	-	-


Table 2 Area under the curve for the prediction of poor response (oocytes ≤ 4) and risk of OHSS (oocytes ≥ 16) after COS using a variety of ovarian response biomarkers (n=41)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


Bland Altman chart for interobserver agreement for determination of total antral follicle count (DM - AA)



Bland Altman chart for interobserver agreement for determination of total antral follicle count (DM - VT)



Bland Altman chart for agreement of total antral follicle count determined in early and late follicular phase of the cycle (iAFC - sAFC)






Dimitrios Mavrelou has been NIHR academic clinical lecturer in Reproductive Medicine at University College London since 2012. He studied medicine at the University of Oxford and Guy's King's St Thomas' School of Medicine. He completed his core Obstetrics and Gynecology training in London and undertook his MD in gynecological ultrasound. He is currently a subspecialty trainee in Reproductive Medicine at University College London Hospital. His research interests include the diagnosis and management of endometriosis, the diagnosis and management of early pregnancy complications, and the impact of gynecological disorders on assisted conception techniques.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

A handwritten signature in black ink, appearing to read 'DM', with a long horizontal flourish extending to the right.

Dr Dimitrios Mavrelos

From: Tabitha.Kavoi@uclh.nhs.uk 
Subject: RE: Audit assessment form
Date: 1 October 2015 at 11:42
To: Onyike.Nmaju@uclh.nhs.uk, d.mavrelos@ucl.ac.uk
Cc: s.braverman@nhs.net



Dear Mr Mavrelos,

Thank you for your email. I can confirm that from the form, your project is not research and therefore does not require ethical review by a NHS or Social Care Research Ethics Committee or management permission through the NHS R&D office. Please approach your clinical audit lead (attached find the list) who will be able to advise on the next steps.

Kind regards,

Tabitha Kavoi
Senior Portfolio Coordinator
Joint Research Office
(part of the Research Support Centre)
1st Floor Maple House (Suite B)
149 Tottenham Court Road
London W1T 7DN

Telephone: 020 3447 5696 Internal: 75696

Fax: 020 3108 2312

Postal Address: Joint Research Office, UCL, Gower Street, London WC1E 6BT

Web: www.ucl.ac.uk/jro

UCLH Research Patient Flag, live on e-CareLogic (CDR) from the 21st September 2015

-----Original Message-----

From: Mavrelos, Dimitrios [mailto:d.mavrelos@ucl.ac.uk]
Sent: 29 September 2015 15:48
To: RandD
Subject: Audit assessment form

Dear R&D,

Please find attached a form for a project we are hoping to undertake in the RMU. I will be grateful for your assessment.

Thank you

Dimitri

Mr Dimitrios Mavrelos
Clinical Lecturer in Reproductive Medicine University College Hospital d.mavrelos@nhs.uk
0044 7958384268

This email is confidential and is intended solely for the person or entity to whom it is addressed. If this is not you, please forward the message to mail.administrator@uclh.nhs.uk. We have scanned this email before sending it, but cannot guarantee that malicious software is absent and we shall carry no liability in this regard.

We advise that information intended to be kept confidential should not be sent by email. We also advise that health concerns should be discussed with a medical professional in person or by telephone. NHS 111 can also provide advice. We shall not be liable for any failure to follow this advice. University College London Hospitals NHS Foundation Trust (UCLH).



Clinical_Audit_Leads_20
15[1].docx

We sought the opinion of the Joint Research Office of the hospital and were advised that formal ethics approval was not required as the project involved no change in routine clinical practice. Please find attached the relevant correspondence.

Dr Dimitrios Mavrelos